reference standard raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-06-17 and is reviewed periodically as new material appears.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Visual inspection is not sufficient for identity. |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water; stock solutions use organic solvent. |
| Storage | -20°C, desiccated, protected from light | Limits hydrolysis and photodegradation. |
| Analytical method | HPLC-UV/MS | Used for identity and purity assessment. |
| Synonyms | SR9009, Stenabolic | Naming varies by supplier. |
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
However a 2020 review concluded that while PCSK9 inhibitor treatment provides additional benefits beyond maximally tolerated statin therapy in high-risk individuals, PCSK9 inhibitor use probably produces little or no difference in mortality. Regeneron Pharmaceuticals (in collaboration with Sanofi) became the first to market a PCSK9 inhibitor, with a competitor Amgen reaching market slightly later. Prices were very high, inhibiting adoption. The drugs are approved by the FDA for treatment of hypercholesterolemia, notably the genetic condition heterozygous familial hypercholesterolemia which causes high cholesterol levels and heart attacks at a young age. These drugs were later approved by the FDA for the reduction of cardiovascular events including a reduction in all-cause mortality. In recent meta-analyses, early initiation of PCSK9 inhibitors within 48 to 72 hours following acute coronary syndrome (ACS) in addition to high dose statin therapy was associated with rapid reduction in LDL-C level, and potentially other lipid profiles such as triglycerides and total cholesterol level at 4 to 12 weeks after the cardiac event. This translates into a significant reduction in ACS-related hospital readmission and the need for coronary revascularization in short-term follow-up at 1 to 18 months. Two monoclonal antibodies that bind to and inhibit PCSK9 near the catalytic domain have since been approved to lower LDL cholesterol: alirocumab (Praluent, Sanofi/Regeneron), approved by the U.S.
As for snack food, the now popular tramezzini were first served in a historic café of downtown Turin, namely Caffè Mulassano, where they were devised in 1925 as an alternative to English tea sandwiches. In recent years, another trademark drink of the city is MoleCola, an Italian cola that entered production in 2012 and quickly spread both in Italy and outside its native country. Local cuisine also features a particular type of pizza, so-called pizza al padellino or pizza al tegamino, which is basically a small-sized, thick-crust and deep-dish pizza typically served in several Turin pizza places. Since the mid-1980s, Piedmont has also benefited from the start of the Slow Food movement and Terra Madre, events that have highlighted the rich agricultural and vinicultural value of the Po Valley and northern Italy.
According to the Ukrainian Air Force, Russia attacked Ukraine's infrastructure with 35 Iranian kamikaze drones, 30 of which were said to have been shot down. 23 of the drones attacked Kyiv (according to the city officials, 18 of them were shot down). An infrastructure facility was damaged, leaving three areas in Kyiv without power. Energy shortages caused interruptions in heat and water supply. Mykolaiv and Kherson regions were also attacked. Building of Kherson Oblast State Administration was partially destroyed.
Sources: en.wikipedia.org
Calcium alginate is used in different types of medical products, including skin wound dressings, in the form of hydrogels, to promote healing, since alginate can increase the fluid uptake capacity of dressings, reducing the amount of times the dressing needs to be changed.
Rees Pughe in Denbighshire and takes the surname "Pughe". Anthony Bushby Bacon sells his share of the Hirwaun ironworks to his brother Thomas and buys the Mathews' estate at Aberaman. Julia Ann Hatton moves to Kidwelly after her husband's death. A stone-built Caerleon Bridge is opened. A new bridge is built across the River Dyfi at Machynlleth. Thomas Jones of Denbigh marries for a third time, to Mary Lloyd. The Prince of Wales makes an impromptu visit to Wales in the company of Sir Richard Puleston. To commemorate the event, he plants a young oak tree.
substrate 1. A chemical compound or molecule upon which a particular enzyme directly acts, often but not necessarily binding the molecule by forming one or more chemical bonds. See also ligand. 2. The substance, biotic or abiotic, upon which an organism grows or lives, or by which it is supported; e.g. a particular growth medium used in cell culture. See also substratum.
Seeded second at the Italian Open, he reached the semifinals defeating Cristian Garín in the quarterfinals. In the semifinals, he faced fourth seed, Stefanos Tsitsipas, again for the third consecutive time at this Masters level in the clay court season. He lost his semifinal match to Tsitsipas in three sets. Seeded third at the French Open, Zverev matched his semifinal result from the previous year, defeating sixth seed, Carlos Alcaraz, in the quarterfinals in what was his first top-10 victory at a major after 12 attempts. In his semifinal match against fifth seed, former world No. 1, and 13 time Roland Garros champion, Rafael Nadal, he retired 3 hours and 13 minutes into the match after rolling his right ankle and tearing all three lateral ligaments. He was rolled off the court in a wheelchair. Zverev informed that the injury would cause him to miss the 2022 Wimbledon Championships and on 8 June 2022 underwent surgery to repair the torn ligaments in his ankle. Despite his exit at Roland Garros, he reached a career-high ranking of world No. 2 on 13 June 2022. In September, he was due to return for the Davis Cup play but suffered a new injury, a bone edema, and withdrew from competition for the rest of the season. Zverev ended the year ranked 12, his lowest in five years, when he debuted in the top 10 and remained a fixture there.
Sources: en.wikipedia.org
Liquid chromatography with mass spectrometry is a common approach. Ultraviolet detection and nuclear magnetic resonance can support identification when suitable standards are available.
The solid is generally kept cold, dry, and protected from light. Solutions are often frozen in single-use aliquots to reduce repeated freeze-thaw cycles.
It indicates a material sold for laboratory study, not for human use. The label does not guarantee pharmaceutical purity, sterility, or regulatory approval.
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.